Who are Unicycive Therapeutics, Inc.'s main suppliers?

Unicycive Therapeutics, Inc. (UNCY) key suppliers include: SHILPA, SPECTRUM-PHARMACEUTICALS-INC. View the full supplier network at chainsifter.com/chain/UNCY.

Who are Unicycive Therapeutics, Inc.'s major customers?

Unicycive Therapeutics, Inc. (UNCY) key customers include: GUGGENHEIM-SECURITIES-LLC. View the full customer network at chainsifter.com/chain/UNCY.

What sector is Unicycive Therapeutics, Inc. in?

Unicycive Therapeutics, Inc. (UNCY) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Unicycive Therapeutics, Inc. (UNCY) Suppliers & Customers

2Suppliers

1Customers

3Debt Items

0Related Chains

Source-Backed Evidence Depth

Unicycive Therapeutics, Inc. (UNCY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

7Total relationships

2Distinct source URLs

6High confidence

0.866Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Unicycive Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
SHILPA	SHILPA	92%	On June 29, 2023 and October 26, 2023, the Company entered into services agreements with Shilpa related to NDA filing support for oxylanthanum carbonate.
SPECTRUM-PHARMACEUTICALS-INC	SPECTRUM-PHARMACEUTICALS-INC	92%	Pursuant to the Spectrum Agreement, in consideration for the Compounds, we issued 313,663 shares of common stock to Spectrum.

Unicycive Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
GUGGENHEIM-SECURITIES-LLC	GUGGENHEIM-SECURITIES-LLC	62%	te. Our net income was $0.6 million and our net loss was $12.8 million for the three months ended March 31, 2025 and 2026, respectively. As of March 31, 2026, we had an accumulated deficit of $140.6 …

Unicycive Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
UNCY-DEBT	Debt stack $815,000	90%	Market cache reports total debt of $815,000.
UNCY-DEBT-13218	Warrants outstanding: 6	90%	xbrl warrant detail from xbrl 2025-12-31.
UNCY-DEBT-13219	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Unicycive Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Unicycive Therapeutics, Inc..

Unicycive Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
UNCY-OWNER-VIVO-CAPITAL-LLC	Vivo Capital, LLC	90%	13F overlay lists Vivo Capital, LLC as top holder; 51 tracked holders.

Unicycive Therapeutics, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.

Unicycive Therapeutics, Inc. Supply Chain